Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial

Filgrastim (G-CSF) use in immunocompetent children with sepsis-induced MOFS is safe, and a 2-dose of filgrastim (G-CSF) for three days has poor efficacy in the reduction of mortality and did not show significant change in frequency of HAI, TNF-α levels, and pSOFA scores.